# A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

> **NCT02791334** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 164 (actual)

## Conditions studied

- Solid Tumor
- Microsatellite Instability-High (MSI-H) Solid Tumors
- Cutaneous Melanoma
- Pancreatic Cancer
- Breast Cancer (HR+HER2-)

## Interventions

- **DRUG:** LY3300054
- **DRUG:** Ramucirumab
- **DRUG:** Abemaciclib
- **DRUG:** Merestinib
- **DRUG:** LY3321367

## Key facts

- **NCT ID:** NCT02791334
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-29
- **Primary completion:** 2020-05-22
- **Final completion:** 2024-06-27
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02791334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02791334, "A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02791334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*